

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/42, C07K 16/06, 16/10	A3	(11) International Publication Number: WO 97/11667 (43) International Publication Date: 3 April 1997 (03.04.97)
(21) International Application Number: PCT/IB96/01115 (22) International Filing Date: 25 September 1996 (25.09.96) (30) Priority Data: 60/004,281 25 September 1995 (25.09.95) US (71)(72) Applicant and Inventor: CHACHOUA, Samir [AU/MX]; 28 Kangaroo Road, Murrembeena, Melbourne, VIC 3163 (AU).		(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 12 June 1997 (12.06.97)
(54) Title: THERAPEUTIC APPLICATIONS USING HORSE SERUM (57) Abstract Novel uses of animal sera including horse sera in the treatment, diagnosis and clinical management of AIDS, cancer and other viral and bacterial diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB96/01115

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 39/42; C07K 16/06, 16/10

US CL : 424/160.1; 530/380, 389.4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/160.1; 530/380, 389.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WEPSIC et al. Effect of Horse Antibody to Rat Alpha-Fetoprotein upon the Growth of AH-66 in Donryu Rats. Int. J. Cancer. 15 May 1980, Vol. 25, No. 5, pages 655-661, see Abstract.	1-47
Y	OHKAWA et al. The Inhibitory Effects of Horse Anti-Rat AFP Antiserum on the Uptake of 2-Deoxy-D-Glucose by AFP-Producing Rat Hepatoma Cells. Int. J. Cancer. 1984, Vol. 33, No. 4, pages 497-502, see Abstract.	1-47
Y	TSUKADA et al. Effect on Anti-Alpha-Fetoprotein Serum on Some Cultured Tumor Cells. Int. J. Cancer. January 1974, Vol. 13, No. 2, pages 187-195, see Abstract.	1-47

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 APRIL 1997

Date of mailing of the international search report

01 MAY 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHUONG BUI

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB96/01115

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MARMONT et al. Positive Direct Antiglobulin Tests and Heteroimmune Hemolysis in Patients with Severe Aplastic Anemia and Pure Red Cell Anemia Treated with Antilymphocytic Globulin. Acta haemat. 1985, Vol. 74, No. 1, pages 14-18, see Abstract.	9, 12-18, 20-39, 44-45, 47
Y	MIHAESCU et al. Treatment of Ascites Tumour with Cytolytic Serum Obtained by Double Immunization. Neoplasma. 1974, Vol. 21, No. 3, pages 297-195, see Abstract.	1-47
Y	BRATKOWSKA-SENIOW et al. Obtaining, Evaluation and Clinical Application of Antileukemic Antilymphocyte Globulin (ALLG) in the Treatment of Chronic Lymphatic Leukemia. Archivum Immunologiae et Therapie Experimentalis. 1977, Vol. 25, No. 3, pages 349-365, see Abstract.	1-47
Y	LAZAREV et al. Inhibition of Subcutaneous Ehrlich Carcinoma by Antihuman-Somatotropic Hormone Serum of the Horse as Determined by the Tumour-Tetanus Assay of the Mouse. Arch. Geschwulstforsch. 1976, Vol. 46, No. 4, pages 261-270, see entire article.	9-18, 20-39, 47
Y	PEREZ et al. HIV-1 and HTLV-1 Infection in Renal Transplant Recipients. J. Acquired Immune Deficiency Syndromes. 1990, Vol. 3, No. 1, pages 35-40, see Abstract.	1, 11-18, 20-31, 36-40, 44, 47
Y	GIRALDI et al. Antitumour Activity of Equinatoxin. Chem.-Biol. Interactions. June 1976, Vol. 13, No. 3/4, pages 199-203, see Abstract.	15-18, 20, 28-29, 35-36, 38
Y	SMITH et al. Experimental Cachexia: Effects of MCA Sarcoma in the Fischer Rat. Am. J. Physiol. 1993, Vol. 265, No. 2, Part 2, pages R376-R384, see Abstract.	44-46
Y	CHODAK et al. Increased Levels of Fibroblast Growth Factor-like Activity in Urine from Patients with Bladder or Kidney Cancer. Cancer Research. 15 April 1988, Vol. 48, No. 8, pages 2083-2088, see Abstract.	32-34
Y	NAKANISHI et al. Direct Effect of Basic Fibroblast Growth Factor on Gene Transcription in a Cell-free System. Proc. Natl. Acad. Sci. USA. June 1992, Vol. 89, No. 12, pages 5216-5220, see Abstract.	32-34

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB96/01115

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHERER et al. The Effect of Antilymphocytic and Normal Horse Serum on Growth of Precancerous Foci and Development of Tumours Induced by Diethylnitrosamine in Rat Liver. Europ. J. Cancer. 1976, Vol. 12, No. 1, pages 25-31, see entire article.	1-47
Y	HIRAI et al. Purification of Specific Antibody to α -Foetoprotein and its Immunological Effect on Cancer Cells. J. Chromatogr. 1981, Vol. 215, pages 195-210, see pages 195-196, Abstract and Introduction.	1-47
Y	NKRUMAH et al. Regression of Progressive Lymphadenopathy in a Young Child with Acute Cytomegalovirus (CMV) Infection Following the Administration of Transfer Factor with Specific Anti-CMV Activity. Lymphokine Research. 1985, Vol. 4, No. 3, pages 237-241, see Introduction.	6-7, 15-16, 36-38
Y	JEWETT et al. Preventive Health Care for Adults with HIV Infection. JAMA. 03 March 1993, Vol. 269, No. 9, pages 1144-1153, see entire article.	1-11, 18-20, 32, 36
Y	GUNNARSSON et al. Effect of Combinations of Cysteamine (Mercaptoethylamine, MEA) and Nucleoside Reverse Transcriptase (RT) Inhibitors on HIV-1 Replication in Vitro. Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. October 1994, page 93, Abstract 192, see entire abstract.	18-20
Y	GIRI et al. Failure of Allogenic Bone Marrow Transplantation to Benefit HIV Infection. J. Paediatr. Child Health. 1992, Vol. 28, No. 4, pages 331-333, see Abstract.	36-38
Y	US 4,228,127 A (ACEVEDO ET AL.) 14 October 1980, Abstract and column 5, line 12.	12-13
Y	US 5,310,653 A (HANAUSEK-WALASZEK ET AL.) 10 May 1994, see Abstract.	12-13